R

ise and shine, everyone, another busy day is on the way. The Pharmalot campus, for instance, is already bustling as our short person has darted out the door for the local schoolhouse and the official mascots are hungrily sniffing about the grounds for wild game. As for us, the coffee kettle is fired up so we can brew delicious cups of stimulation. So time to dig into the tidbits below and get your game going. Have a wonderful day and do keep in touch …

The Food and Drug Administration approved a three-in-one lung inhaler from GlaxoSmithKline (GSK) for treating chronic lung disease, Reuters tells us. Trelegy Ellipta, which is the first such treatment for chronic obstructive pulmonary disease, is a key new product for the drug maker, which is scrambling to keep its lead in respiratory medicines despite falling sales of its older Advair drug.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy